pentolinium

Trade name: ansolysen

Small moleculeapproved

Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves. — NCATS

Clinical trial activity

0 trials · 0 clinical orgs · 2 marketing orgs

Phase 1

Phase 2

Phase 3

Phase 4

Timeline

1950s

Dec 21, 1954
Wyeth — First NDA Organization
Dec 21, 1954
Wyeth — NDA Organization

Indications

Approved for

Hypertension

Mechanism of action

Neuronal acetylcholine receptor; alpha3/beta4ANTAGONIST
Neuronal acetylcholine receptor; alpha3/beta4 antagonist
- Neuronal acetylcholine receptor subunit beta-4 (CHRNB4) ↗
- Neuronal acetylcholine receptor subunit alpha-3 (CHRNA3) ↗
- Neuronal acetylcholine receptor subunit alpha-3

Approval history

approved—

Chemistry & pharmacology

Loading structure…

SMILES

C[N+]1(CCCCC[N+]2(C)CCCC2)CCCC1

Mol. weight: 240.44 g/mol
Lipinski Ro5: Pass
Rule of 3: No
Chirality: Achiral Molecule
Inorganic: No
Polymer: No
Delivery: Parenteral
Availability: Discontinued

Oral

Parenteral

Yes

Topical

Sources

Also known as

ansolysen
ansolysen
ansolysen
ansolysen
pentapyrrolidinium
pentolineum
pentolineum
pentolinium
pentolinium
pentolinium
pentolinium
pentolinium
pentolinium
pentolinium
pentolinium bitartrate
pentolinium tartrate
pentolinium tartrate
pentolinium tartrate
pentolinium tartrate
pentolonium
pentolonium
pentolonium
pentolonium
pentolonium tartrate
pentolonium tartrate
pentolonium tartrate
pentolonum
pentolonum
pentolonum bitartrate
pentolonum bitartrate

Organizations

Marketing (2)

Organization	Org type	Relationship	Date
American Home Products	For profit	NDA2	—
Wyeth	For profit	NDA	Dec 21, 1954